Updates
-
-
Home Care for Peripheral Neuropathy Foot Pain
The peripheral symptoms associated with familial amyloid polyneuropathy include sensations in the feet that range from numbness to burning. Caregivers looking for ways to provide ... Read more -
AKCEA-TTR-LRx Reduces Levels of TTR in Healthy Volunteers, Phase 1 Trial Shows
Akcea Therapeutics’ next-generation antisense medicine AKCEA-TTR-LRx (ION-682884) — currently in development for the treatment of all forms of familial amyloid polyneuropathy (FAP) — reduces ... Read more -
Responding to Weather Changes When Caring for Neuropathy Patients
Patients with familial amyloid polyneuropathy may find that changes in seasons increase discomfort. Colder temperatures require layers of clothing that may bother someone with ... Read more -
Alexion Obtains Japanese Rights to Potential FAP Therapy AG10; Phase 3 Trial Planned
Alexion Pharmaceuticals has obtained exclusive rights in Japan to develop and market AG10, an oral treatment candidate for familial amyloid polyneuropathy (FAP), also called ATTR polyneuropathy ... Read more -
Questions to Ask When Caregivers Consider Relocating
Caregivers of familial amyloid polyneuropathy patients may find themselves in a tough situation when their jobs require them to move. Balancing a career with ... Read more
Subscribe to our mailing list
Get regular updates delivered to your email box.
Thanks! Please check your email for a confirmation email.
-
Angel loved growing up in a big, close-knit family, surrounded by cousins, aunts and ...
-
Massage Therapy May Relieve Neuropathy Symptoms
Pain associated with peripheral neuropathy symptoms can lead to serious health complications later in ... -
At NY Genome Center, Legal Expert Presents Ethical Dilemmas in Gene Editing
Developing gene therapies for rare diseases is one thing. Creating gene-edited “designer babies” is ... -
Lower Cathepsin E Levels Could Underlie Impaired Function of Macrophages in FAP, Study Suggests
The lower levels of a protein called cathepsin E, upon activation of a type ...
Tafamidis Delays Disease Progression in Patients with Transthyretin Amyloid Polyneuropathy, Pfizer Study Suggests
News
An interim analysis of the Phase 3 trial for tafamidis (Fx-1006A) as a therapy for patients with hereditary transthyretin amyloid polyneuropathy (TTR-FAP) shows the investigational treatment delays disease progression, Pfizer announced. The study, “Long-term safety and efficacy of tafamidis for ... Read more